The Role of Cytoskeleton Protein 4.1 in Immunotherapy
Abstract
:1. Introduction
2. Immunoregulation and Tumor Microenvironment
3. Cytoskeleton Protein 4.1
4. The Role of Cytoskeleton Protein 4.1 in Immunoregulation and Cancer
5. Function of Cytoskeleton Protein 4.1
5.1. Protein 4.1R
5.2. Protein 4.1N
5.3. Protein 4.1B
6. Clinical Application of Cytoskeleton Protein 4.1 in the Tumor Microenvironment
6.1. Cytoskeleton Protein 4.1 May Be a Biomarker in Cancer
6.2. Cytoskeleton Protein 4.1 May Be a Therapeutic Target in Cancer
7. Conclusions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Irvine, D.; Dane, E. Enhancing cancer immunotherapy with nanomedicine. Nat. Rev. Immunol. 2020, 20, 321–334. [Google Scholar] [CrossRef] [PubMed]
- Kennedy, L.; Salama, A. A review of cancer immunotherapy toxicity. CA Cancer J. Clin. 2020, 70, 86–104. [Google Scholar] [CrossRef] [PubMed]
- Riley, R.; June, C.; Langer, R.; Mitchell, M. Delivery technologies for cancer immunotherapy. Nat. Rev. Drug. Discov. 2019, 18, 175–196. [Google Scholar] [CrossRef]
- Waldman, A.; Fritz, J.; Lenardo, M. A guide to cancer immunotherapy: From T cell basic science to clinical practice. Nat. Rev. Immunol. 2020, 20, 651–668. [Google Scholar] [CrossRef] [PubMed]
- Guevara, M.; Persano, F.; Persano, S. Nano-immunotherapy: Overcoming tumour immune evasion. Semin. Cancer Biol. 2021, 69, 238–248. [Google Scholar] [CrossRef]
- Ramez, M.; Blot-Chabaud, M.; Cluzeaud, F.; Chanan, S.; Patterson, M.; Walensky, L.; Marfatia, S.; Baines, A.; Chasis, J.; Conboy, J.; et al. Distinct distribution of specific members of protein 4.1 gene family in the mouse nephron. Kidney Int. 2003, 63, 1321–1337. [Google Scholar] [CrossRef]
- Wang, Z.; Zhang, J.; Ye, M.; Zhu, M.; Zhang, B.; Roy, M.; Liu, J.; An, X. Tumor suppressor role of protein 4.1B/DAL-1. Cell. Mol. Life Sci. 2014, 71, 4815–4830. [Google Scholar] [CrossRef]
- Liang, T.; Guo, Y.; Li, M.; Ding, C.; Sang, S.; Zhou, T.; Shao, Q.; Liu, X.; Lu, J.; Ji, Z.; et al. Cytoskeleton protein 4.1R regulates B-cell fate by modulating the canonical NF-kappaB pathway. Immunology 2020, 161, 314–324. [Google Scholar] [CrossRef]
- Chen, L.; Wang, T.; Ji, X.; Ding, C.; Liang, T.; Liu, X.; Lu, J.; Guo, X.; Kang, Q.; Ji, Z. Cytoskeleton protein 4.1R suppresses murine keratinocyte cell hyperproliferation via activating the Akt/ERK pathway in an EGFR-dependent manner. Exp. Cell. Res. 2019, 384, 111648. [Google Scholar] [CrossRef]
- Sagiv-Barfi, I.; Czerwinski, D.; Shree, T.; Lohmeyer, J.; Levy, R. Intratumoral immunotherapy relies on B and T cell collaboration. Sci. Immunol. 2022, 7, eabn5859. [Google Scholar] [CrossRef]
- Ganesh, K.; Massague, J. Targeting metastatic cancer. Nat. Med. 2021, 27, 34–44. [Google Scholar] [CrossRef] [PubMed]
- Bergers, G.; Fendt, S. The metabolism of cancer cells during metastasis. Nat. Rev. Cancer 2021, 21, 162–180. [Google Scholar] [CrossRef] [PubMed]
- Yu, W.; Hu, C.; Gao, H. Advances of nanomedicines in breast cancer metastasis treatment targeting different metastatic stages. Adv. Drug Deliv. Rev. 2021, 178, 113909. [Google Scholar] [CrossRef]
- Bhat, A.; Nisar, S.; Maacha, S.; Carneiro-Lobo, T.; Akhtar, S.; Siveen, K.; Wani, N.; Rizwan, A.; Bagga, P.; Singh, M.; et al. Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy. Mol. Cancer 2021, 20, 2. [Google Scholar] [CrossRef]
- Hegde, P.; Chen, D. Top 10 Challenges in Cancer Immunotherapy. Immunity 2020, 52, 17–35. [Google Scholar] [CrossRef]
- Chen, D.; Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 2017, 541, 321–330. [Google Scholar] [CrossRef] [PubMed]
- Tumeh, P.; Harview, C.; Yearley, J.; Shintaku, I.; Taylor, E.; Robert, L.; Chmielowski, B.; Spasic, M.; Henry, G.; Ciobanu, V.; et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515, 568–571. [Google Scholar] [CrossRef]
- Haase, K.; Offeddu, G.; Gillrie, M.; Kamm, R. Endothelial Regulation of Drug Transport in a 3D Vascularized Tumor Model. Adv. Funct. Mater. 2020, 30, 2002444. [Google Scholar] [CrossRef]
- Qu, Y.; Dou, B.; Tan, H.; Feng, Y.; Wang, N.; Wang, D. Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment. Mol. Cancer 2019, 18, 69. [Google Scholar] [CrossRef]
- Altorki, N.; Markowitz, G.; Gao, D.; Port, J.; Saxena, A.; Stiles, B.; McGraw, T.; Mittal, V. The lung microenvironment: An important regulator of tumour growth and metastasis. Nat. Rev. Cancer 2019, 19, 9–31. [Google Scholar] [CrossRef] [Green Version]
- Gorgun, G.; Whitehill, G.; Anderson, J.; Hideshima, T.; Maguire, C.; Laubach, J.; Raje, N.; Munshi, N.; Richardson, P.; Anderson, K. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 2013, 121, 2975–2987. [Google Scholar] [CrossRef] [PubMed]
- Xu, M.; Zhang, T.; Xia, R.; Wei, Y.; Wei, X. Targeting the tumor stroma for cancer therapy. Mol. Cancer 2022, 21, 208. [Google Scholar] [CrossRef] [PubMed]
- Fitzgerald, R.; Antoniou, A.; Fruk, L. Rosenfeld. The future of early cancer detection. Nat. Med. 2022, 28, 666–677. [Google Scholar] [CrossRef] [PubMed]
- Hoover, K.; Bryant, P. The genetics of the protein 4.1 family: Organizers of the membrane and cytoskeleton. Curr. Opin. Cell. Biol. 2000, 12, 229–234. [Google Scholar] [CrossRef] [PubMed]
- Schischmanoff, P.; Yaswen, P.; Parra, M.; Lee, G.; Chasis, J.; Mohandas, N.; Conboy, J. Cell shape-dependent regulation of protein 4.1 alternative pre-mRNA splicing in mammary epithelial cells. J. Biol. Chem. 1997, 272, 10254–10259. [Google Scholar] [CrossRef]
- Horresh, I.; Bar, V.; Kissil, J.; Peles, E. Organization of myelinated axons by Caspr and Caspr2 requires the cytoskeletal adapter protein 4.1B. J. Neurosci. 2010, 30, 2480–2489. [Google Scholar] [CrossRef]
- Wang, J.; Song, J.; An, C.; Dong, W.; Zhang, J.; Yin, C.; Hale, J.; Baines, A.; Mohandas, N.; An, X. A 130-kDa protein 4.1B regulates cell adhesion, spreading, and migration of mouse embryo fibroblasts by influencing actin cytoskeleton organization. J. Biol. Chem. 2014, 289, 5925–5937. [Google Scholar] [CrossRef]
- Chen, L.; Hughes, R.; Baines, A.; Conboy, J.; Mohandas, N.; An, X. Protein 4.1R regulates cell adhesion, spreading, migration and motility of mouse keratinocytes by modulating surface expression of beta1 integrin. J. Cell Sci. 2011, 124, 2478–2487. [Google Scholar] [CrossRef]
- Zhang, Y.; He, J. Tumor vasculature-targeting nanomedicines. Acta Biomater. 2021, 134, 1–12. [Google Scholar] [CrossRef]
- Scheetz, L.; Park, K.; Li, Q.; Lowenstein, P.; Castro, M.; Schwendeman, A.; Moon, J. Engineering patient-specific cancer immunotherapies. Nat. Biomed. Eng. 2019, 3, 768–782. [Google Scholar] [CrossRef]
- Joshi, S.; Badgwell, B. Current treatment and recent progress in gastric cancer. CA Cancer J. Clin. 2021, 71, 264–279. [Google Scholar] [CrossRef] [PubMed]
- Bagchi, S.; Yuan, R.; Engleman, E. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annu. Rev. Pathol. 2021, 16, 223–249. [Google Scholar] [CrossRef] [PubMed]
- Mao, X.; Xu, J.; Wang, W.; Liang, C.; Hua, J.; Liu, J.; Zhang, B.; Meng, Q.; Shi, X.Y.S. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: New findings and future perspectives. Mol. Cancer 2021, 20, 131. [Google Scholar] [CrossRef]
- Bernkopf, D.; Williams, E. Potential role of EPB41L3 (protein 4.1B/Dal-1) as a target for treatment of advanced prostate cancer. Expert Opin. Ther. Targets 2008, 12, 845–853. [Google Scholar] [CrossRef] [PubMed]
- Dafou, D.; Grun, B.; Sinclair, J.; Lawrenson, K.; Benjamin, E.; Hogdall, E.; Kruger-Kjaer, S.; Christensen, L.; Sowter, H.; Al-Attar, A.; et al. Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers. Neoplasia 2010, 12, 579–589. [Google Scholar] [CrossRef] [PubMed]
- Conboy, J.; Kan, Y.; Shohet, S.; Mohandas, N. Molecular cloning of protein 4.1, a major structural element of the human erythrocyte membrane skeleton. Proc. Natl. Acad. Sci. USA 1986, 83, 9512–9516. [Google Scholar] [CrossRef] [PubMed]
- Fan, D.; Li, J.; Li, Y.; Guo, Y.; Zhang, X.; Wang, W.; Liu, X.; Liu, J.; Dai, L.; Zhang, L.; et al. Protein 4.1R negatively regulates CD8(+) T-cell activation by modulating phosphorylation of linker for activation of T cells. Immunology 2019, 157, 312–321. [Google Scholar]
- Lu, Y.; Fan, D.; Wang, W.; Gao, X.; Li, H.; Guo, S.; Zhao, L.; Guo, Y.; Li, B.; Zhong, Y.; et al. The protein 4.1R downregulates VEGFA in M2 macrophages to inhibit colon cancer metastasis. Exp. Cell. Res. 2021, 409, 112896. [Google Scholar] [CrossRef]
- Walensky, L.; Blackshaw, S.; Liao, D.; Watkins, C.; Weier, H.; Parra, M.; Huganir, R.; Conboy, J.; Mohandas, N.; Snyder, S. A novel neuron-enriched homolog of the erythrocyte membrane cytoskeletal protein 4.1. J. Neurosci. 1999, 19, 6457–6467. [Google Scholar] [CrossRef]
- Liang, T.; Sang, S.; Shao, Q.; Chen, C.; Deng, Z.; Wang, T.; Kang, Q. Abnormal expression and prognostic significance of EPB41L1 in kidney renal clear cell carcinoma based on data mining. Cancer Cell Int. 2020, 20, 356. [Google Scholar] [CrossRef]
- Kikuchi, S.; Yamada, D.; Fukami, T.; Masuda, M.; Sakurai-Yageta, M.; Williams, Y.; Maruyama, T.; Asamura, H.; Matsuno, Y.; Onizuka, M.; et al. Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer. Clin. Cancer Res. 2005, 11, 2954–2961. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wong, S.; Haack, H.; Kissil, J.; Barry, M.; Bronson, R.; Shen, S.; Whittaker, C.; Crowley, D.; Hynes, R. Protein 4.1B suppresses prostate cancer progression and metastasis. Proc. Natl. Acad. Sci. USA 2007, 104, 12784–12789. [Google Scholar] [CrossRef] [PubMed]
- Yang, S.; Weng, H.; Chen, L.; Guo, X.; Parra, M.; Conboy, J.; Debnath, G.; Lambert, A.; Peters, L.; Baines, A.; et al. Lack of protein 4.1G causes altered expression and localization of the cell adhesion molecule nectin-like 4 in testis and can cause male infertility. Mol. Cell Biol. 2011, 31, 2276–2286. [Google Scholar] [CrossRef]
- Ralston, K.; Hird, S.; Zhang, X.; Scott, J.; Jin, B.; Thorne, R.; Berndt, M.; Boyd, A.; Burns, G. The LFA-1-associated molecule PTA-1 (CD226) on T cells forms a dynamic molecular complex with protein 4.1G and human discs large. J. Biol. Chem. 2004, 279, 33816–33828. [Google Scholar] [CrossRef] [PubMed]
- Rutland, J.; Gill, C.; Loewenstern, J.; Arib, H.; Pain, M.; Umphlett, M.; Kinoshita, Y.; McBride, R.; Bederson, J.; Donovan, M.; et al. NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas. Cancer Immunol. Immunother. 2021, 70, 169–176. [Google Scholar] [CrossRef]
- Robb, V.; Li, W.; Gascard, P.; Perry, A.; Mohandas, N.; Gutmann, D. Identification of a third Protein 4.1 tumor suppressor, Protein 4.1R, in meningioma pathogenesis. Neurobiol. Dis. 2003, 13, 191–202. [Google Scholar] [CrossRef] [PubMed]
- Jeremy, K.; Plummer, Z.; Head, D.; Madgett, T.; Sanders, K.; Wallington, A.; Storry, J.; Gilsanz, F.; Delaunay, J.; Avent, N. 4.1R-deficient human red blood cells have altered phosphatidylserine exposure pathways and are deficient in CD44 and CD47 glycoproteins. Haematologica 2009, 94, 1354–1361. [Google Scholar] [CrossRef]
- Pavan, A.; Attili, I.; Pasello, G.; Guarneri, V.; Conte, P.; Bonanno, L. Immunotherapy in small-cell lung cancer: From molecular promises to clinical challenges. J. Immunother. Cancer 2019, 7, 205. [Google Scholar] [CrossRef]
- Funaki, T.; Ito, T.; Tanei, Z.; Goto, A.; Niki, T.; Matsubara, D.; Murakami, Y. CADM1 promotes malignant features of small-cell lung cancer by recruiting 4.1R to the plasma membrane. Biochem. Biophys. Res. Commun. 2021, 534, 172–178. [Google Scholar] [CrossRef] [PubMed]
- Kuroki, L.; Guntupalli, S. Treatment of epithelial ovarian cancer. BMJ 2020, 371, m3773. [Google Scholar] [CrossRef]
- Xi, C.; Ren, C.; Hu, A.; Lin, J.; Yao, Q.; Wang, Y.; Gao, Z.; An, X.; Liu, C. Defective expression of Protein 4.1N is correlated to tumor progression, aggressive behaviors and chemotherapy resistance in epithelial ovarian cancer. Gynecol. Oncol. 2013, 131, 764–771. [Google Scholar] [CrossRef]
- Liang, Y.; Zhang, H.; Song, X.; Yang, Q. Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. Semin. Cancer Biol. 2020, 60, 14–27. [Google Scholar] [CrossRef]
- Ji, Z.; Shi, X.; Liu, X.; Shi, Y.; Zhou, Q.; Liu, X.; Li, L.; Ji, X.; Gao, Y.; Qi, Y.; et al. The membrane-cytoskeletal protein 4.1N is involved in the process of cell adhesion, migration and invasion of breast cancer cells. Exp. Ther. Med. 2012, 4, 736–740. [Google Scholar] [CrossRef]
- Wang, Z.; Ma, B.; Li, H.; Xiao, X.; Zhou, W.; Liu, F.; Zhang, B.; Zhu, M.; Yang, Q.; Zeng, Y.; et al. Correction: Protein 4.1N acts as a potential tumor suppressor linking PP1 to JNK-c-Jun pathway regulation in NSCLC. Oncotarget 2019, 10, 6285. [Google Scholar] [CrossRef]
- Smyth, E.; Nilsson, M.; Grabsch, H.; van Grieken, N.; Lordick, F. Gastric cancer. Lancet 2020, 396, 635–648. [Google Scholar] [CrossRef] [PubMed]
- Liu, Q.; Zhang, J.; Gao, H.; Yuan, T.; Kang, J.; Jin, L.; Gui, S.; Zhang, Y. Role of EGFL7/EGFR-signaling pathway in migration and invasion of growth hormone-producing pituitary adenomas. Sci. China Life Sci. 2018, 61, 893–901. [Google Scholar] [CrossRef] [PubMed]
- Xue, F.; An, C.; Chen, L.; Liu, G.; Ren, F.; Guo, X.; Sun, H.; Mei, L.; Sun, X.; Li, J.; et al. 4.1B suppresses cancer cell proliferation by binding to EGFR P13 region of intracellular juxtamembrane segment. Cell. Commun. Signal. 2019, 17, 115. [Google Scholar] [CrossRef]
- Jiang, W.; Newsham, I. The tumor suppressor DAL-1/4.1B and protein methylation cooperate in inducing apoptosis in MCF-7 breast cancer cells. Mol. Cancer 2006, 5, 4. [Google Scholar] [CrossRef]
- Nassiri, F.; Liu, J.; Patil, V.; Mamatjan, Y.; Wang, J.; Hugh-White, R.; Macklin, A.; Khan, S.; Singh, O.; Karimi, S.; et al. A clinically applicable integrative molecular classification of meningiomas. Nature 2021, 597, 119–125. [Google Scholar] [CrossRef] [PubMed]
- Gerber, M.; Bahr, S.; Gutmann, D. Protein 4.1B/differentially expressed in adenocarcinoma of the lung-1 functions as a growth suppressor in meningioma cells by activating Rac1-dependent c-Jun-NH(2)-kinase signaling. Cancer Res. 2006, 66, 5295–5303. [Google Scholar] [CrossRef]
- Wang, L.; Xu, M.; Kao, C.; Tsai, S.; Tsai, M. Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1. J. Clin. Invest. 2020, 130, 1782–1792. [Google Scholar] [CrossRef] [Green Version]
- Rini, B.; Campbell, S.; Escudier, B. Renal cell carcinoma. Lancet 2009, 373, 1119–1132. [Google Scholar] [CrossRef] [PubMed]
- Nagata, M.; Sakurai-Yageta, M.; Yamada, D.; Goto, A.; Ito, A.; Fukuhara, H.; Kume, H.; Morikawa, T.; Fukayama, M.; Homma, Y.; et al. Aberrations of a cell adhesion molecule CADM4 in renal clear cell carcinoma. Int. J. Cancer 2012, 130, 1329–1337. [Google Scholar] [CrossRef]
- Yuan, X.; Piao, L.; Wang, L.; Han, X.; Zhuang, M.; Liu, Z. [Corrigendum] Pivotal roles of protein 4.1B/DAL-1, a FERM-domain containing protein, in tumor progression (Review). Int. J. Oncol. 2020, 56, 641. [Google Scholar] [CrossRef]
- Kwong, G.; Ghosh, S.; Gamboa, L.; Patriotis, C.; Srivastava, S.; Bhatia, S. Synthetic biomarkers: A twenty-first century path to early cancer detection. Nat. Rev. Cancer 2021, 21, 655–668. [Google Scholar] [CrossRef]
- Doroshow, D.; Bhalla, S.; Beasley, M.; Sholl, L.; Kerr, K.; Gnjatic, S.; Wistuba; Rimm, D.; Tsao, M.; Hirsch, F. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 2021, 18, 345–362. [Google Scholar] [CrossRef]
- Normanno, N.; Apostolidis, K.; de Lorenzo, F.; Beer, P.; Henderson, R.; Sullivan, R.; Biankin, A.; Horgan, D.; Lawler, M. Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems. Semin. Cancer Biol. 2022, 84, 293–301. [Google Scholar] [CrossRef]
- Shen, Z.; Song, J.; Yung, B.; Zhou, Z.; Wu, A.; Chen, X. Emerging Strategies of Cancer Therapy Based on Ferroptosis. Adv. Mater. 2018, 30, e1704007. [Google Scholar] [CrossRef]
- Topalian, S.; Taube, J.; Anders, R.; Pardoll, D. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 2016, 16, 275–287. [Google Scholar] [CrossRef]
- Draberova, L.; Draberova, H.; Potuckova, L.; Halova, I.; Bambouskova, M.; Mohandas, N.; Draber, P. Cytoskeletal Protein 4.1R Is a Positive Regulator of the FcepsilonRI Signaling and Chemotaxis in Mast Cells. Front. Immunol. 2019, 10, 3068. [Google Scholar] [CrossRef]
- Conboy, J.; Chan, J.; Mohandas, N.; Kan, Y. Multiple protein 4.1 isoforms produced by alternative splicing in human erythroid cells. Proc. Natl. Acad. Sci. USA 1988, 85, 9062–9065. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yuan, J.; Xing, H.; Li, Y.; Song, Y.; Zhang, N.; Xie, M.; Liu, J.; Xu, Y.; Shen, Y.; Wang, B.; et al. EPB41 suppresses the Wnt/beta-catenin signaling in non-small cell lung cancer by sponging ALDOC. Cancer Lett. 2021, 499, 255–264. [Google Scholar] [CrossRef] [PubMed]
- O’Donnell, J.S.; Teng, M.; Smyth, M. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 2019, 16, 151–167. [Google Scholar] [CrossRef]
- Liu, K.; Cui, J.; Zhan, Y.; Ouyang, Q.; Lu, Q.; Yang, D.; Li, X.; Yin, J. Reprogramming the tumor microenvironment by genome editing for precision cancer therapy. Mol. Cancer 2022, 21, 98. [Google Scholar] [CrossRef]
- Hiam-Galvez, K.; Allen, B.; Spitzer, M. Systemic immunity in cancer. Nat. Rev. Cancer 2021, 21, 345–359. [Google Scholar] [CrossRef]
- Li, B.; Zhang, X.; Lu, Y.; Zhao, L.; Guo, Y.; Guo, S.; Kang, Q.; Liu, J.; Dai, L.; Zhang, L.; et al. Protein 4.1R affects photodynamic therapy for B16 melanoma by regulating the transport of 5-aminolevulinic acid. Exp. Cell Res. 2021, 399, 112465. [Google Scholar] [CrossRef]
- Taylor-Harris, P.; Felkin, L.; Birks, E.; Franklin, R.; Yacoub, M.; Baines, A.; Barton, P.; Pinder, J. Expression of human membrane skeleton protein genes for protein 4.1 and betaIISigma2-spectrin assayed by real-time RT-PCR. Cell Mol. Biol. Lett. 2005, 10, 135–149. [Google Scholar]
- Si, C.; Chen, C.; Guo, Y.; Kang, Q.; Sun, Z. Effect, Mechanism, and Applications of Coding/Non-coding RNA m6A Modification in Tumor Microenvironment. Front. Cell Dev. Biol. 2021, 9, 711815. [Google Scholar] [CrossRef]
- Baghban, R.; Roshangar, L.; Jahanban-Esfahlan, R.; Seidi, K.; Ebrahimi-Kalan, A.; Jaymand, M.; Kolahian, S.; Javaheri, T.; Tumor, P.Z. microenvironment complexity and therapeutic implications at a glance. Cell Commun. Signal. 2020, 18, 59. [Google Scholar] [CrossRef] [Green Version]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Si, C.; Yuan, L.; Chen, C.; Wang, T.; Kang, Q. The Role of Cytoskeleton Protein 4.1 in Immunotherapy. Int. J. Mol. Sci. 2023, 24, 3777. https://doi.org/10.3390/ijms24043777
Si C, Yuan L, Chen C, Wang T, Kang Q. The Role of Cytoskeleton Protein 4.1 in Immunotherapy. International Journal of Molecular Sciences. 2023; 24(4):3777. https://doi.org/10.3390/ijms24043777
Chicago/Turabian StyleSi, Chaohua, Lihua Yuan, Chen Chen, Ting Wang, and Qiaozhen Kang. 2023. "The Role of Cytoskeleton Protein 4.1 in Immunotherapy" International Journal of Molecular Sciences 24, no. 4: 3777. https://doi.org/10.3390/ijms24043777